Obermatt
See Similar Stocks →

Adaptive Biotechnologies

NSQ:ADPT · US00650F1093
Life Sciences Tools & ServicesMedium

360

20
Profit price96
Owner Earnings Yield1
Dividend Yield1
Price/Sales62
EV / Gross Profit7
Price/Book11
Return on Capital21
Cash Return on Capital23
Return on Equity18
EBIT Margin22
Gross Profitability70
Accruals77
Owner Earnings Margin32
Sales growth44
Profit growth80
Reinvestment40
Price momentum69
Debt load13
Refinancing89
Debt Payback1
Liquidity82
Analyst ratings34
Opinion Changes50
Price Target Upside25
Market mood41
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Adaptive Biotechnologies clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2009
Employees627
Websiteadaptivebiotech.com
ISINUS00650F1093
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsOncologyImmunologyMachine LearningHematologyVaccinesArtificial IntelligenceGeneticsBiotechnologyHealth CareTherapeutics

Description

Adaptive Biotechnologies Corporation is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The company's immune medi…

Analysis

Middle-of-the-road

Adaptive Biotechnologies Corporation sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 10/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
69
2023202420252026

All-time high

94

Jan 2024

All-time low

21

Jan 2023

Average rank

57

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
62
39
59
17
Price/Earnings
95
60
60
10
Price/Book
11
4
60
55
Dividend Yield
1
1
1
1
Value (overall)
36
6
55
25

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Adaptive Biotechnologies with its peers
Caribou Biosciences
NSQ:CRBU
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Protara Therapeutics
NMQ:TARA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tyra Biosciences
NSQ:TYRA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Geron
NSQ:GERN
22
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Personalis
NMQ:PSNL
8
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →